ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.…
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals (NASDAQ: ORIC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 119 employees.
The shares were at 7.360 USD on 20 November 2026, down 41.4% over 52 weeks. Its 52-week range is 7.230 USD to 14.68 USD: the price is 49.9% below the high and 1.8% above the low.
Its market capitalisation is 764.94M USD.
ORIC Pharmaceuticals reports return on equity of -33.7% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 255.42M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 14 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 21.29 USD is 189.2% above the current price. The next earnings report is expected on 22 February 2027.